Novocure (NASDAQ: NVCR) reported Q3 EPS of ($0.13), $0.06 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $133.6 million versus the consensus estimate of $141.76 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.